Long-term follow-up of patients with glaucoma after micro-interventional eye surgery
Collects 3, 4 and 5-year follow-up data on glaucoma patients after CycloPen eye surgery.
Plain-language title generated from the registry record
Registry title: 5-Year Postoperative Outcomes of Patients Who Completed the CREST Study
Key facts
- Where
- Atlanta, Cape Coral, Chevy Chase, Crossville, DeLand, Fort Washington, Las Vegas, Newport Beach, Rockville, and Salt Lake City, United StatesSee the 10 sites
Where in United States
- AtlantaAtlanta, United StatesNo longer taking part
- Cape CoralCape Coral, United StatesNo longer taking part
- Chevy ChaseChevy Chase, United StatesNo longer taking part
- CrossvilleCrossville, United StatesNo longer taking part
- DeLandDeLand, United StatesNo longer taking part
- Fort WashingtonFort Washington, United StatesNo longer taking part
- Las VegasLas Vegas, United StatesNo longer taking part
- Newport BeachNewport Beach, United StatesNo longer taking part
- RockvilleRockville, United StatesNo longer taking part
- Salt Lake CitySalt Lake City, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Iantrek, Inc.
- Trial code
- NCT07480343
- Record updated
- 21 July 2026
- Original description
This study is designed to collect clinical data at 3, 4, and 5 years postoperatively for participants who completed the CREST Study without having secondary IOP-lowering surgery in the study eye(s).Read full original descriptionShow less
FIVE-YEAR POSTOPERATIVE OUTCOMES IN PATIENTS WITH OPEN-ANGLE GLAUCOMA WHO UNDERWENT BIO-INTERVENTIONAL UVEOSCLERAL OUTFLOW ENHANCEMENT SURGERY: LONG-TERM OBSERVATIONAL FOLLOW-UP FROM THE CREST STUDY (THE CREST-XT STUDY)
This study is designed to collect clinical data at 3, 4, and 5 years postoperatively for participants who completed the CREST Study without having secondary IOP-lowering surgery in the study eye(s).
Inclusion: Diagnosis of open-angle glaucoma (OAG) in the study eye(s), including pigmentary and pseudoexfoliative glaucoma, at the time of CREST enrollment; Completed participation in CREST; Provide signed written consent using the Institutional Review Board (IRB)/Ethics Committee (EC) approved study-specific informed consent form (ICF); Ability, comprehension, and willingness to follow study instructions.
Exclusion: Secondary surgical intervention for long-term IOP control in the study eye(s); Systemic disease that, in the opinion of the Investigator, would put participant's health at risk and/or prevent completion of required study visits; Early termination from CREST.